Privium Fund Management B.V. Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Privium Fund Management B.V. decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 14.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 484,500 shares of the company's stock after selling 83,295 shares during the quarter. Roivant Sciences accounts for approximately 1.4% of Privium Fund Management B.V.'s portfolio, making the stock its 22nd largest position. Privium Fund Management B.V. owned about 0.07% of Roivant Sciences worth $5,116,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its stake in shares of Roivant Sciences by 81.0% in the fourth quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company's stock valued at $213,370,000 after acquiring an additional 8,500,000 shares in the last quarter. Norges Bank acquired a new stake in Roivant Sciences in the 4th quarter valued at about $41,506,000. First Trust Advisors LP boosted its stake in shares of Roivant Sciences by 434.8% in the 4th quarter. First Trust Advisors LP now owns 2,739,438 shares of the company's stock valued at $30,764,000 after buying an additional 2,227,192 shares during the period. Penn Davis Mcfarland Inc. acquired a new position in shares of Roivant Sciences during the first quarter worth about $17,287,000. Finally, BlackBarn Capital Partners LP purchased a new stake in shares of Roivant Sciences during the fourth quarter worth approximately $17,406,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded up $0.21 during midday trading on Friday, hitting $12.23. The stock had a trading volume of 5,081,470 shares, compared to its average volume of 4,097,170. The company has a market capitalization of $9.03 billion, a PE ratio of 2.42 and a beta of 1.24. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.24. The stock has a 50 day moving average price of $11.07 and a two-hundred day moving average price of $11.00. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. The business had revenue of $55.10 million during the quarter, compared to analysts' expectations of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company's quarterly revenue was up 155.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.38) EPS. As a group, equities analysts predict that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ROIV. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, June 18th. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, July 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday, August 19th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $17.10.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.